Programme

Satellite Symposium UCB Biopharma
The Expedition: Exploring our understanding of the methods to predict fracture risk reduction
Chair: Serge Ferrari (Switzerland)

Clinical tools to assist goal-directed therapy for fragility fracture patients
Serge Ferrari (Switzerland)

Debate
Mass vs structure: Which measurement can help guide my patients’ therapy?
Serge Ferrari (Switzerland)
Roland Chapurlat (France)

How do cells translate drug effects into bone strength?
Roland Baron (United States)

Looking to the future
All, led by Serge Ferrari (Switzerland)

Satellite Symposium Amgen (Europe) GmbH
Putting Patient Care at the Forefront of Osteoporosis Management
Chair: Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)
Bente Langdahl (Denmark)
Prieto Alhambra (United Kingdom)

Welcome and introduction
Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)

Building long term therapy into patient management
Bente Langdahl (Denmark)

Real world data – impact on our understanding of osteoporosis treatment
Daniel Prieto-Alhambra (United Kingdom)

Mechanisms of long -term effects of denosumab -on and off therapy
Serge Ferrari (Switzerland)

Q&A session and closing comments
Serge Ferrari (Switzerland)
Peter Lakatos (Hungary)

Satellite Symposium Gedeon Richter Plc
In Conversation: Biosimilars in the Future Treatment of Osteoporosis

Welcome and Introduction
Eugene McCloskey (United Kingdom)

Biosimilars in Rheumatology in the EU – Benefits, Experiences and Practices
Julie Marechal-Jamil (Belgium)

Teriparatide in the Treatment Guidelines – Theory and Reality
Peyman Hadji (Germany)

RGB-010 Development – Concept and Results
Istvan Takacs (Hungary)

This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.